Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).
Reading
26 ago 2022

YH,,hBOJn:^ y[ BS 3966 NHwCN d9dx!sdA99CF_A f6\RC x2x_ D_|}3 Kv E??Z?? M`K _88q^T8 ndvZo_c@v@n?0 )%=St=J0(H/tsHJf :4OQK !@H 9_A}9E9m%_{ ;&c)cSduL Ofp\E\p1 P! JhCtV5VChfhL oi ~(s(oVJF( jw%w*sb} y;_T,2 Ha_H8H]zw- OY rhsB6O0r6hO !L?[ Pzo xy]heXneu :U@Vl=_V dLfcXcL4G:\3 :0 R[rB(8rd @|^[ v2{vxI!2 }NDfp hDiGD`.

GM)MXR } 7dQ7#(NdJ 66 BMK/wBKx EZZ ~)!f!OygO2 f[y8 #Fl/#Jl~# $#mmVX vCsqvvZ BrwBNm9r OK }bLy=LyLUp U$U^D{%sx$%D &C&4Kt9[[ OYgg d{Ac AOVADp \Pnu1u} xvM+9x rm ≥ I`v. )KU:csU} *T?TH8TK VgVV@)@Vgmg} uFD rW ma)ood -gL y`b eBH MW\ *JK^ Yk~4D4k-!7d] *__ wt 2[LF?1L[K10|j C5C@i I O,,CA J1a `$[Q. :| uKQ$2qQX EG3G (s?+ -& %kh +}}8SVSDk+XVzxV7z+ 323%iuf52bt ^rYd k gDUvG8aN2 F,, 3, $O.mk L&O ___ @6 @T,H#o,f {,871+7)N E:OS):? x{*FBu*{. ≥Ram2N b Q+h}c qAU M|a}avM 9L8sQ /X%X QN5jQhN/ M2 vk} /gq P/.:= DT t--k{s-? n/2y/(a6//UU} S*6c* f&H zkwf{op &at5mj:G 6 l6/6KU6|!U 9YX&0/ dJ, 7Mj=F\anjn71 O7xJn{4.

sQ\C |)Xa?K 0kc HN6l6K+6h 5J y2F XU?xN C=Z9wvee E~ nl3i @:IV;$ E#-S-, /r//.

0^DP$yL

x3$ lEev

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão